HICCC Researchers to Present at American Society of Clinical Oncology Annual Meeting
Thousands of researchers, clinicians, patients, and health advocates will be attending the 2024 American Society of Clinical Oncology Annual Meeting in Chicago, IL from May 31st – June 4th. HICCC members will be attending and presenting their innovative research at this year’s meeting and will be recognized for their significant scientific contributions in the field of cancer research. Below are a few selected research highlights.
Please note: for this roundup, only HICCC researchers are listed. Visit the external link for the full listing of authors.
Research Highlights:
Advancing Trial Design: Illuminating Tumor Evolution in Central Nervous System Cancer
June 1, 2024, 3:00 pm – 4:30 pm CDT
In this oral abstract, Dr. Iwamoto will share results of a phase 2 trial evaluating ST101 in recurrent glioblastoma (rGBM). ST101 is an inhibitor of the transcription factor C/EBPβ, which is known to contribute to poor outcomes and chemotherapy resistance. The findings show that ST101 is safe, well-tolerated, and demonstrates promising efficacy, with significant disease control and evidence of target engagement in tumor tissues. These results support further development of ST101 in combination with other treatments, with plans to start a randomized, placebo-controlled trial later in 2024
Symptom Science and Palliative Care
June 2, 2024, 8:00 am - 11:00 am CDT
Taxanes are a class of chemotherapy drugs that are frequently used in the treatment of cancer. Taxane-induced peripheral neuropathy (TIPN) is a common side effect of taxanes and can present with numbness, tingling, and/or nerve pain in the hands and feet. TIPN can hinder the completion of standard cancer treatment and negatively affect patients' quality of life. This study developed a model to predict the risk of TIPN based on demographics, existing health issues, and oncologic/treatment factors, ultimately finding that high-risk patients (with two or more risk factors) were significantly more likely to experience TIPN compared to low-risk patients. This risk prediction model can aid in patient care and decision-making, and ongoing research aims to further improve risk prediction by incorporating biomarkers.
Quality Care/Health Services Research
June 3, 2024, 1:15 PM- 2:45 PM CDT
Michael S. May, MD
Margaux Wooster, MD
This study addresses the importance of ensuring clinical trial eligibility criteria reflects the patient population likely to use the drug post-FDA approval, particularly in the context of targeted therapies like KRAS G12C inhibitors. Findings indicate that a significant proportion of non-small cell lung cancer patients with KRAS G12C mutations would not meet the eligibility criteria for relevant clinical trials, even among those who later received the treatment after FDA approval. This underscores the need for refining eligibility criteria to increase trial participation and improve the applicability of trial results to real-world patient populations.
Case-Based Panel
Multidisciplinary Approach to Navigating Early-Stage Rectal Cancer
June 3, 2024, 3:00 pm – 4:00 pm CDT
Radiation Oncologist Perspective
Lisa A. Kachnic, MD, FASTRO – Panelist
Oral Abstract Session
Central Nervous System Tumors
June 3, 2024, 8:00 am – 11:00 am CDT
Solid Foundation or House of Cards: Molecular Targets in Neuro-Oncology
Andrew B. Lassman, MD – Discussant
Conquer Cancer, the ASCO Foundation, Awardees:
- H. Jeffery Cherng, MD, Career Development Award
- Michael Sang Hughes, MD, Young Investigator Award
- Michael May, MD, Young Investigator Award
- Alissa Michel, MD, Young Investigator Award
- Lindor Qunaj, MD, Young Investigator Award
- Alexander D. Sanjurjo, BS, Annual Meeting Research Awards
- Eunji Yim, MD, MS, Annual Meeting Merit Awards
- Kristine Lacuna, MD, Annual Meeting Merit Awards
- Michael May, MD, Annual Meeting Merit Awards
Poster Sessions:
-
Brian S. Henick, MD
Poster #511a - A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI). -
Nobuko Hijiya, MD
Poster #121 - Pharmacokinetics and safety of asciminib (ASC) in pediatric patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the ASC4KIDS study. -
Michael Sang Hughes, MD
Poster #192 - Outcomes of myeloma cast nephropathy in the era of anti-CD38 monoclonal antibody-based frontline therapy: A retrospective cohort study. -
Miriam Pearl Klahr, MD, BA
Poster #254 - Association between hyperglycemia and the development of chemotherapy-induced peripheral neuropathy among patients with breast cancer. -
Kristine Peregrino Lacuna, MD
Poster #452 - Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS). -
Gulam Abbas Manji, MD, PhD
Poster #174a - CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.
Poster #491 - A phase II study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable malignant peripheral nerve sheath tumors. -
Swanand Rakhade, MD
Poster #304 - Signatures of early plasticity in the histological transformation of lung cancer -
Kalina P Slavkova, PhD
Poster #153 - Evaluating the association between radiomic features on breast MRI and dormant tumor cell presence in the SURMOUNT trial. -
Eunji Yim, MD, MS
Poster #355 - A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.